Article

74 views

YL Biologics’ biosimilar candidate, YLB113 demonstrated equivalence to the Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® (etanercept). Indian generic pharma giant, Lupin and Japanese drug maker, Yoshindo’s joint venture- YL Biologics’ (YLB) etanercept biosimilar candidate, YLB113 showed equivalent…..

YL Biologics’ biosimilar candidate, YLB113 demonstrated equivalence to the Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® (etanercept). Indian generic pharma giant, Lupin and Japanese drug maker, Yoshindo’s joint venture- YL Biologics’ (YLB) etanercept biosimilar candidate, YLB113 showed equivalent…..

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in DRUG TRIAL


DRUG TRIAL

8 Most Promising Vaccines Under Development (2018)

Vaccines protect against a large spectrum of infections. The eradication of deadly smallpox in the past and lately the declining statistics of polio are the most wonderful examples of the effect of the vaccine on humans. Here are some of the most promising vaccines on their way in 2018. Continue reading.. Total Word Counts: 1431

DRUG TRIAL

Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer

Pfizer’s investigational agent, lorlatinib, a next-generation ALK/ROS1 tyrosine kinase inhibitor received Priority Review status from the US FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC)....continue reading

DRUG TRIAL

Lupin & Yoshindo’s First Enbrel Biosimilar Targets Regulatory Approval

YL Biologics’ biosimilar candidate, YLB113 demonstrated equivalence to the Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® (etanercept). Indian generic pharma giant, Lupin and Japanese drug maker, Yoshindo’s joint venture- YL Biologics’ (YLB) etanercept biosimilar candidate, YLB113 showed equivalent.....

DRUG TRIAL

US FDA Fast Tracked Takeda’s Zika Virus Vaccine

Takeda’s inactivated, whole Zika virus vaccine candidate- TAK-426 (PIZV) received ‘fast track’ status from the US FDA.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.

MARKET INSIGHTS

9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..

Leave a reply